Stocks Trend Analysis: The Blackstone Group L.P. (BX) AMAG Pharmaceuticals, Inc. (AMAG) Fifth Third Bancorp (FITB)

The Blackstone Group L.P. (BX) continued its downward trend with the stock declining -1.31% or $-0.4 to close the day at $30.07 on active trading volume of 5.26M shares, compared to its three month average trading volume of 5.02M. The New York New York 10154 based company has been outperforming the asset management group over the past 52 weeks, with the stock gaining 29.95%, compared to the industry which has advanced 25.59% over the same period. With RSI of 65.97, the stock should still continue to rise and get closer to its one year target estimate of $32.92, making it a hold for now.

The Blackstone Group L.P. is a publicly owned hedge fund sponsor. The firm also provides financial advisory services to its clients. It provides its services to public and corporate pension funds, academic, cultural, and charitable organizations, retirees, sovereign wealth funds, and institutional and individual investors. The firm manages separate client focused portfolios for its clients. It launches fixed income mutual funds. The firm also launches and manages private equity funds, real estate funds, funds of hedge funds, and credit-focused funds for its clients. It invests in private equity, public equity, fixed income, and alternative investment markets. The Blackstone Group L.P. was founded in 1985 and is based in New York, New York with additional offices in London, United Kingdom, Hong Kong, Beijing, China, Dubai, UAE, Dusseldorf, Germany, Los Angeles, Santa Monica, Mexico City, Mexico, Paris, France, Sao Paulo, Brazil, Seoul, Korea, Shanghai, China, Singapore, Sydney, Australia, Copenhagen, Denmark, and Tokyo, Japan.

AMAG Pharmaceuticals, Inc. (AMAG) grew with the stock adding 0.43% or $0.1 to close at $23.1 on active trading volume of 5.26M compared its three months average trading volume of 1.09M. The Waltham Massachusetts 02451 based company operating under the Diagnostic Substances industry has been trending down for the last 52 weeks, with the shares price now -1.07% down for the period and down by -33.62% so far this year. With price target of $37.4 and a 28.91% rebound from 52-week low, AMAG Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.

AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units. In addition, it has a license agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Fifth Third Bancorp (FITB) managed to rebound with the stock climbing 1.16% or $0.31 to close the day at $27.07 on lower than average trading volume of 5.24M shares, compared to its three month average trading volume of 7.76M. The Cincinnati Ohio 45263 based company has been outperforming the regional – midwest banks companies by 31.3246% for last three months and its recent gains have pushed the stock slightly up 0.37% YTD, versus the regional – midwest banks industry which is down -0.22% for the same period. The RSI of 57.56 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Fifth Third Bancorp operates as a diversified financial services company in the United States. It operates through four segments: Commercial Banking, Branch Banking, Consumer Lending, and Investment Advisors. The Commercial Banking segment offers credit intermediation, cash management, and financial services; lending and depository products; and foreign exchange and international trade finance, derivatives and capital markets services, asset-based lending, real estate finance, public finance, commercial leasing, and syndicated finance for business, government, and professional customers. The Branch Banking segment provides deposit and loan products to individuals and small businesses. This segment offers checking and savings accounts, home equity loans and lines of credit, credit cards, and loans for automobiles and personal financing needs. The Consumer Lending segment engages in direct lending activities that include origination, retention, and servicing of residential mortgage and home equity loans or lines of credit; and indirect lending activities, including loans to consumers through correspondent lenders and automobile dealers. The Investment Advisors segment provides various investment alternatives for individuals, companies, and not-for-profit organizations. It offers retail brokerage services to individual clients; and broker dealer services to the institutional marketplace. This segment also provides asset management services; holistic strategies to affluent clients in wealth planning, investing, insurance, and wealth protection; and advisory services for institutional clients comprising states and municipalities. As of December 31, 2015, the company operated 1,254 full-service banking centers, including 95 Bank Mart locations, as well as 2,593 automated teller machines in 12 states throughout the Midwestern and Southeastern regions of the United States. Fifth Third Bancorp was founded in 1862 and is headquartered in Cincinnati, Ohio.

 

Traders Recap: AMAG Pharmaceuticals, Inc. (AMAG), Dycom Industries, Inc. (DY), Kennametal Inc. (KMT)

AMAG Pharmaceuticals, Inc. (AMAG) managed to rebound with the stock climbing 4.15% or $1.33 to close the day at $33.23 on lower than average trading volume of 0.86M shares, compared to its three month average trading volume of 739.68K. The Waltham Massachusetts 02451 based company has been underperforming the diagnostic substances companies by 40.4331% for last three months and its recent gains have pushed the stock slightly up 10.05% YTD, versus the diagnostic substances industry which is up 23.17% for the same period. The RSI of 61.35 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units. In addition, it has a license agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Dycom Industries, Inc. (DY) had a light trading with around 0.86M shares changing hands compared to its three month average trading volume of 840.77K. The stock traded between $71.26 and $72.56 before closing at the price of $71.34 with -1.61% change on the day. The Palm Beach Gardens Florida 33408 based company is currently trading 51.46% above its 52 week low of $47.1 and -27.54% below its 52 week high of $98.45. Both the RSI indicator and target price of 35.4 and $103.17 respectively, lead us to believe that it should be put on hold over the coming weeks.

Dycom Industries, Inc. provides specialty contracting services in the United States and Canada. The company offers various specialty contracting services, such as engineering, construction, maintenance, and installation services comprising placement and splicing of fiber, copper, and coaxial cables to telecommunications providers. It also provides tower construction, lines and antenna installation, and foundation and equipment pad construction for wireless carriers, as well as equipment installation and material fabrication, and site testing services; and installs and maintains customer premise equipment, such as digital video recorders, set top boxes, and modems for cable television system operators. In addition, the company offers underground facility locating services, such as locating telephone, cable television, power, water, sewer, and gas lines for various utility companies, including telecommunication providers. Further, it provides construction and maintenance services for electric and gas utilities, and other customers. Dycom Industries, Inc. was founded in 1969 and is based in Palm Beach Gardens, Florida.

Kennametal Inc. (KMT) traded within a range of $33.86 to $34.72 after opening the day at $34.62. The company has seen its stock increase in value by 84.17% so far this year. The stock was down close to -1.44% on light volume in last trading session and closed at $34.17 per share. After the recent fall, the stock is currently holding -4.18% below its 52 week high of $35.66 and 134.02% above its 12-month low of $15.11. The shares are up by over 21.31% in the last three months, and the RSI indicator value of 59.62 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Kennametal Inc. provides wear-resistant products, application engineering, and services of material science to the industrial production, transportation, earthworks, energy, construction, process industries, and aerospace sectors worldwide. The company operates through two segments, Industrial and Infrastructure. Its product offering includes a selection of standard and customized technologies for metalworking, such as metal cutting tools, tooling systems, and services, as well as high-performance materials, such as cemented tungsten carbide products, super alloys, coatings, and investment castings to address customer demands. The company also supplies tooling, engineered components, and advanced materials consumed in production processes. In addition, it develops and manufactures metalworking tools and wear-resistant engineered components and coatings using a specialized type of powder metallurgy; manufactures and markets a line of tool holders, tool-holding systems, and rotary-cutting tools by machining and fabricating steel bars and other metal alloys; and produces specialized compacts and metallurgical powders, as well as products made from tungsten carbide or other hard materials that are used for custom-engineered and challenging applications, including mining and highway construction. Further, the company develops, manufactures, and markets engineered components and surface technology solutions with proprietary metal cladding capabilities. It sells its products through its direct sales force; and network of independent distributors and sales agents; and integrated supply channels, as well as via the Internet. Kennametal Inc. was founded in 1938 and is based in Pittsburgh, Pennsylvania.

 

Stock’s Trend Analysis Report: Fifth Street Finance Corp. (FSC), NetScout Systems, Inc. (NTCT), AMAG Pharmaceuticals, Inc. (AMAG)

Fifth Street Finance Corp. (FSC) fell -2.89% during last trading as the stock lost $-0.18 to finish the day at $6.05 with about 0.91M shares changing hands, compared to its three month average trading volume of 702.59K. The $874.89M market cap company, which fluctuated between $6.04 and $6.24 during the day, currently situated 47.25% above its 52 week low of $4.4 and -4.27% away from its one year high of $6.77. The RSI of 55.33 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

NetScout Systems, Inc. (NTCT) dropped $-0.92 to close the day at a new closing price of $28.18, a -3.16% decrease in value from its previous closing price that moved the stock 50.13% above its 52 week low of $18.77. A total of 0.91M shares exchanged hands during the day compared with its three month average trading volume of 765.92K. The stock, which fluctuated between $28.16 and $29.26 during the day, currently situated -30.04% below its 52 week high. The stock is up by 1.66% in the past one month and up by 18.06% over the past three months. With a one year target estimate of $31 and RSI of 46.31, the stock still has upside potential, making it a hold for now.

NetScout Systems, Inc. provides real-time operational intelligence and performance analytics for service assurance, and cyber security solutions in the United States, Europe, Asia, and internationally. The company offers nGeniusONE management software that enables customers to predict, preempt, and resolve network and service delivery problems, as well as facilitate the optimization and capacity planning of their network infrastructures; and specialized platforms and analytic modules that enable its customers to analyze and troubleshoot traffic in radio access and Wi-Fi networks, as well as gain timely insight into services, applications, and systems. It also provides Intelligent Data Sources under the Infinistream brand name that provide real-time collection and analysis of data from the network; network monitoring fabric switching solutions that deliver targeted network traffic access to an increasing number of monitoring systems; and a suite of test access points that enable non-disruptive access to network traffic with multiple link type and speed options. In addition, the company offers portable network analysis and troubleshooting tools, which help customers identify key issues that impact network and application performance. Further, it provides security solutions that enable service providers and enterprises to protect their networks against DDoS attacks; and threat detection solutions that enable enterprises to identify and investigate advanced threat campaigns that present tangible risks to the integrity of their networks. The company serves enterprise customers in industries, such as financial services, technology, manufacturing, healthcare, utilities, education, transportation, and retail; mobile operators, wireline operators, and cable operators; and governmental agencies through a direct sales force, and indirect reseller and distribution channels. NetScout Systems, Inc. was founded in 1984 and is headquartered in Westford, Massachusetts.

AMAG Pharmaceuticals, Inc. (AMAG) had a light trading with around 0.91M shares changing hands compared to its three month average trading volume of 891.48K. The stock traded between $22.39 and $23.2 before closing at the price of $22.41 with -3.07% change on the day. The Waltham Massachusetts 02451 based company is currently trading 25.06% above its 52 week low of $17.92 and -64.8% below its 52 week high of $54.24. Both the RSI indicator and target price of 35.4 and $43 respectively, lead us to believe that it should be put on hold over the coming weeks.

AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units. In addition, it has a license agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

 

Stocks in the Spotlight: xG Technology, Inc. (XGTI), AMAG Pharmaceuticals, Inc. (AMAG), Juno Therapeutics Inc. (JUNO)

xG Technology, Inc. (XGTI) had a light trading with around 0.96M shares changing hands compared to its three month average trading volume of 8.72M. The stock traded between $0.454 and $0.4801 before closing at the price of $0.46 with 1.18% change on the day. The Sarasota Florida 34236 based company is currently trading 569.56% above its 52 week low of $0.4 and -84.3% below its 52 week high of $11.28. Both the RSI indicator and target price of 48.89 and $3 respectively, lead us to believe that it should be put on hold over the coming weeks.

xG Technology, Inc. engages in the development of communication technologies for wireless networks worldwide. The company’s intellectual property is embedded in proprietary software algorithms designed to offer cognitive interference mitigation and spectrum access solutions to organizations in a various industries, including national defense and rural broadband. Its products include xMax, a mobile voice over Internet protocol (VoIP) and broadband data system that utilizes an end-to-end Internet protocol (IP) system architecture, which incorporates OFDM and multiple in multiple out and orthogonal frequency-division multiple to increase interference tolerance, allow mobility, and improve resistance to fading. The company’s xMax comprise CN5100 mobile hotspot, a device that allows users of Wi-Fi enabled smartphones, tablets, notebooks, and other devices to access the Internet through the xMax cognitive radio network; CN3100 vehicle modem, which acts as a transparent protocol bridge allowing users of WiFi-enabled devices to access the Internet through the xMax cognitive radio network; CN3200 dual-band routing modem for use in fixed and mobile applications; CN1100 Access Point, an IP wireless access point that delivers wide area coverage and broadband throughput for fixed, nomadic, and mobile applications; and CN7000 Mobile Control Center, which controls the delivery of voice and data services, and manages various elements in the regional network. It also offers xMonitor, which monitors the status and health of various access points, mobile control center elements, and VoIP core elements; and xDrive, a drive mapping utility designed to gather, display, and log performance statistics from mobile hotspot, dual-band routing modem, and CN3100 vehicle modem. The company sells its intellectual property and the equipment directly, as well as through an indirect channel network. xG Technology, Inc. was founded in 2002 and is headquartered in Sarasota, Florida.

AMAG Pharmaceuticals, Inc. (AMAG) continued its upward trend with the stock climbing 5.85% or $1.35 to close the day at $24.44 on light trading volume of 0.96M shares, compared to its three month average trading volume of 962.42K. The Waltham Massachusetts 02451 based company has been underperforming the diagnostic substances group over the past 52 weeks, with the stock losing -61.45%, compared to the industry which has advanced 9.95% over the same period. With RSI of 45.69, the stock should still continue to rise and get closer to its one year target estimate of $40.14, making it a hold for now.

AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units. In addition, it has a license agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Juno Therapeutics Inc. (JUNO) shares were up in last trading by 3.29% to $32.66. It experienced lighter than average volume on day. The stock increased in value by almost 3.81% over the past week and grew 13.4% in the past month. It is currently trading -9.79% below its 50 day moving average and -18.44% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -43.51% decrease in value from its one year high of $57.82. The RSI indicator value of 50.34, lead us to believe that it is a hold for now.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company’s additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. Juno Therapeutics, Inc. has collaboration agreements with Celgene Corporation, Editas Medicine, Inc., Fate Therapeutics, Inc., MedImmune Limited, and Memorial Sloan Kettering Cancer Center. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.

 

Stocks Buzz: Range Resources Corporation (RRC) JetBlue Airways Corporation (JBLU) AMAG Pharmaceuticals, Inc. (AMAG)

Range Resources Corporation (RRC) continued its downward trend with the stock declining -1.75% or $-0.68 to close the day at $38.16 on active trading volume of 4.31M shares, compared to its three month average trading volume of 3.83M. The Fort Worth Texas 76102 based company has been underperforming the independent oil & gas group over the past 52 weeks, with the stock losing -0.63%, compared to the industry which has dropped -1.6% over the same period. With RSI of 36.38, the stock should still continue to rise and get closer to its one year target estimate of $48.84, making it a hold for now.

Range Resources Corporation operates as an independent natural gas, natural gas liquids (NGLs), and oil company. It engages in the exploration, development, and acquisition of natural gas and oil properties. The company holds interests in developed and undeveloped natural gas and oil leases in the Appalachian region of the United States. It owns and operates 4,462 net producing wells and approximately 905,000 net acres under lease in the Appalachian region; and 444 net producing wells and approximately 308,000 net acres under lease in the Texas Panhandle, as well as in the Anadarko Basin of western Oklahoma, the Nemaha Uplift of Northern Oklahoma and Kansas, the Permian Basin of West Texas, and Mississippi. The company markets and sells natural gas to utilities, marketing and midstream companies, and industrial users; NGLs to natural gas processors or users of NGLs; and oil and condensate to crude oil processors, transporters, and refining and marketing companies. As of December 31, 2015, it had proved reserves of 9.9 trillion cubic feet of natural gas equivalents. The company was formerly known as Lomak Petroleum, Inc. and changed its name to Range Resources Corporation in 1998. Range Resources Corporation was founded in 1975 and is headquartered in Fort Worth, Texas.

JetBlue Airways Corporation (JBLU) grew with the stock adding 0.76% or $0.13 to close at $17.13 on light trading volume of 4.3M compared its three months average trading volume of 6.21M. The Long Island City New York 11101 based company operating under the Regional Airlines industry has been trending down for the last 52 weeks, with the shares price now -27.38% down for the period and down by -24.37% so far this year. With price target of $22.64 and a 16.06% rebound from 52-week low, JetBlue Airways Corporation has plenty of upside potential, making it a hold with a view buy.

JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 25 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 Embraer E190 aircrafts. It also served 93 destinations in 28 states in the United States, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, and 19 countries in the Caribbean and Latin America. JetBlue Airways Corporation was founded in 1998 and is based in Long Island City, New York.

AMAG Pharmaceuticals, Inc. (AMAG) continued its downward trend with the stock declining -12.54% or $-3.2 to close the day at $22.31 on lower than average trading volume of 4.27M shares, compared to its three month average trading volume of 901.40K. The Waltham Massachusetts 02451 based company has been outperforming the diagnostic substances companies by 17.856% for last three months and its recent gains have offset losses to -26.1% YTD, versus the diagnostic substances industry which is up 19.8% for the same period. The RSI of 35.04 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units. In addition, it has a license agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Stocks in Focus: Equity One (EQY), Zimmer Biomet (ZBH), AMAG Pharmaceuticals (AMAG)

Equity One Inc. (EQY) had a light trading with around 0.85M shares changing hands compared to its three month average trading volume of 1.05M. The stock traded between $31.59 and $31.85 before closing at the price of $31.75 with -0.16% change on the day. The North Miami Beach Florida 33179 based company is currently trading 45.73% above its 52 week low of $22.52 and -2.49% below its 52 week high of $32.56. Both the RSI indicator and target price of 59.67 and $29.73 respectively, lead us to believe that it should be put on hold over the coming weeks.

Equity One, Inc is a real estate investment trust. The firm invests in the real estate markets of United States. It owns, manages, acquires, develops and redevelops shopping centers and retail properties. Equity One, Inc was formed in 1992 is based in the New York, New York with additional offices in New York City; Marietta, Georgia and Daly City, California. Equity One, Inc. operates as a subsidiary of Popular North America, Inc.

Zimmer Biomet Holdings, Inc. (ZBH) failed to extend gains with the stock declining -0.69% or $-0.87 to close the day at $125.42 on light trading volume of 0.85M shares, compared to its three month average trading volume of 1.61M. The Warsaw Indiana 46581 based company has been outperforming the medical appliances & equipment group over the past 52 weeks, with the stock gaining 17.41%, compared to the industry which has advanced 10.99% over the same period. With RSI of 66.24, the stock should still continue to rise and get closer to its one year target estimate of $127.68, making it a hold for now.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, provides musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Americas Spine, Bone Healing, Craniomaxillofacial and Thoracic (CMF), and Dental. It designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip reconstructive products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and spine products comprising medical devices and surgical instruments. The company also offers face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. In addition, it provides bone cement and bone healing products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

AMAG Pharmaceuticals, Inc. (AMAG) shares were up in last trading by 0.31% to $25.61. It experienced lighter than average volume on day. The stock increased in value by almost 1.67% over the past week and grew 8.56% in the past month. It is currently trading 16.67% above its 50 day moving average and -3.11% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -67.05% decrease in value from its one year high of $76.71. The RSI indicator value of 65.27, lead us to believe that it is a hold for now.

AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units. In addition, it has a license agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

 

The Insider Activity Don’t Lie: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)

AMAG Pharmaceuticals, Inc. (AMAG) up 1.73 per cent in the past week, is under coverage of 9 analysts who collectively recommend a hold rating on stock. 5 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 8 equity analysts who rate the stock have an average target price at $45.13, with individual targets ranging between $27 and $80. The shares closed last trade at $21.8, implying that analysts see shares rising about 107.02 per cent in 12 months’ time.

Insider Activity: Insiders look mixed about the prospects of the company that they seem to trade shares both ways while they are -27.79 down so far this year. A Director at AMAG Pharmaceuticals, Inc. (AMAG) purchased shares in the company in a transaction completed on Tuesday November 10, 2015. Fallon John A. accumulated 3,230 shares in the company at an average price of $31.2 and ended up spending $100,780 in the investment. Fallon John A. now have 6,086 shares in the company after this transaction. A CEO in the company, Heiden William K, on Thursday October 01, 2015 collected $79,380 from the sale of 2,000 shares at $31.2 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering AMAG stock at the going market price of $21.8/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $1.2 in earnings per share (EPS). That would represent a 7.14% year-over-year increase. Revenue for the same period is expected to arrive at $128.7M.

Earnings Roundup: In the last fiscal quarter alone, AMAG Pharmaceuticals, Inc. generated around $117.86M in revenue and net income of $0.94/share. That compares with the consensus estimate $124.83M and $1.11/share, respectively. For the prior quarter revenue for the company hit $108.74M, with earnings at $1.12/share.

Analyst Coverage: Raymond James has been a brokerage house following shares of AMAG Pharmaceuticals, Inc. (AMAG), so its rating change is noteworthy. The stock was downgraded to Mkt Perform from Outperform, wrote analysts at Raymond James, in a note issued to clients on Wednesday May 04, 2016. There was another key note issued by Barclays on Thursday January 21, 2016. The firm launched coverage on AMAG at Equal Weight.

Price Momentum: Despite the 3.61% increase in value, the stock’s new closing price represents a -71.95% fall in value from company’s one year high of $77.73. The stock is currently holding above its 50 day moving average of $-4.28 and above its 200 day moving average of $21.46. Over the last three months and over the last six months, the shares of AMAG Pharmaceuticals, Inc. (AMAG), have changed -27.21% and 24.2%, respectively.